Dengue fever future or investigational therapies
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dengue fever future or investigational therapies |
|
Dengue fever future or investigational therapies in the news |
|
Risk calculators and risk factors for Dengue fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Although there is no commercially available vaccine, there are several ongoing vaccine development programs.
Vaccine Development
There is no commercially available vaccine for the dengue flavivirus. However, a new tetravalent vaccine has been investigated for efficacy and safety in a phase III randomized, observer masked, placebo controlled, multicenter trial in the Asian-Pacific countries. The novel vaccine is a recombinant live attenuated tetravalent vaccine (CYD-TDV) administered at 0 month, 6 months and 12 months. In the Phase III clinical trial, 10275 healthy children 2 to 14 years of age were randomized to either the vaccine or to placebo and were followed up for the occurrence of dengue 28 days after the last vaccine administration.
During a 25 month follow up period, 250 cases of confirmed dengue occurred.
Inhibitors of Viral Replication
Emerging evidence suggests that mycophenolic acid and ribivirin inhibit Dengue fever virus replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.[2] In vivo studies, however, have not yet been done.